Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Intangibles (2022 - 2025)

Rocket Pharmaceuticals' Intangibles history spans 4 years, with the latest figure at $25.2 million for Q3 2025.

  • For Q3 2025, Intangibles changed 0.0% year-over-year to $25.2 million; the TTM value through Sep 2025 reached $25.2 million, changed 0.0%, while the annual FY2024 figure was $25.2 million, 0.0% changed from the prior year.
  • Intangibles for Q3 2025 was $25.2 million at Rocket Pharmaceuticals, roughly flat from $25.2 million in the prior quarter.
  • Across five years, Intangibles topped out at $25.7 million in Q4 2022 and bottomed at $25.2 million in Q4 2023.
  • The 4-year median for Intangibles is $25.2 million (2023), against an average of $25.2 million.
  • The largest annual shift saw Intangibles fell 2.23% in 2023 before it changed 0.0% in 2024.
  • A 4-year view of Intangibles shows it stood at $25.7 million in 2022, then decreased by 2.23% to $25.2 million in 2023, then changed by 0.0% to $25.2 million in 2024, then changed by 0.0% to $25.2 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Intangibles are $25.2 million (Q3 2025), $25.2 million (Q1 2025), and $25.2 million (Q4 2024).